RCM Technologies, Inc. — Form 10-K Summary
Period clarification: Although the request metadata says “2022 Q4,” this filing is RCM Technologies’ annual report for the fiscal year ended December 30, 2023, comparing results with the fiscal year ended December 31, 2022. Both fiscal years had 52 weeks. The filing was signed March 14, 2024.
Business context
RCM provides specialty health care staffing and teletherapy, engineering and project services, and life sciences and information technology services. Fiscal 2023 revenue mix was Specialty Health Care 51.7%, Engineering 32.2%, and Life Sciences and IT 16.1%. The company operates primarily in North America; 6.3% of revenue came from outside the United States.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $263.2 million | $284.7 million |
| Gross profit / margin | $76.7 million / 29.1% | $82.9 million / 29.1% |
| Operating income / margin | $23.7 million / 9.0% | $28.8 million / 10.1% |
| Net income / margin | $16.8 million / 6.4% | $20.9 million / 7.3% |
| Diluted earnings per share | $1.96 | $2.00 |
| Cash from operating activities | $12.5 million | $28.3 million |
| Cash and cash equivalents at year-end | $6.3 million | $0.3 million |
Gross margin was unchanged year over year, but SG&A rose to 19.8% of revenue from 18.8%, and operating and net margins declined. FY2023 adjusted EBITDA, a non-GAAP measure, was $26.6 million, compared with $31.1 million; GAAP net income was $16.8 million versus $20.9 million.
At December 30, 2023, current assets were $90.5 million and current liabilities $58.2 million, for working capital of $32.3 million. Accounts receivable, net, was $70.7 million. Line-of-credit borrowings were $30.8 million; the $45.0 million revolving facility had $12.1 million of additional availability after $2.0 million of letters of credit. The facility matures April 24, 2026, is secured by substantially all company assets and subsidiary stock, and carries variable rates. The weighted-average rate including unused fees was 6.5% in FY2023, versus 2.2% in FY2022. The company reported covenant compliance.
Changes versus FY2022
- Revenue fell 7.5% ($21.4 million), principally as Specialty Health Care revenue declined 14.6% ($23.2 million). Management attributed this mainly to lower COVID-related demand. Engineering revenue decreased 1.5%; Life Sciences and IT revenue increased 7.7%.
- Specialty Health Care operating income declined to $13.5 million from $19.8 million. Engineering operating income fell to $3.5 million from $4.3 million, with lower utilization and margin. Life Sciences and IT operating income improved to $6.6 million from $4.7 million, as gross margin rose to 38.2% from 33.9%.
- Operating cash flow decreased by $15.8 million. A $20.6 million use of cash from increased accounts receivable was partly offset by a $15.7 million cash contribution from the increase in net transit payables, associated with large EPC projects.
- Financing activity included $25.8 million of share repurchases, compared with $17.6 million in FY2022. Net borrowing under the credit line helped fund capital returns; debt increased from $8.8 million to $30.8 million.
Outlook, risks and unusual items
- Management says it believes it can meet liquidity needs for at least the next 12 months and expects to maintain credit-facility covenant compliance. It sees potential for Specialty Health Care growth, subject to seasonality, and is pursuing higher-margin solutions, internal growth and selective acquisitions. The filing provides no quantified revenue or earnings guidance.
- Key risks include economic and client-spending cyclicality, competitive pricing, hiring and retention, customer concentration, collection of receivables, and exposure to variable interest rates and foreign exchange. Two customers each contributed more than 10% of FY2023 revenue (17.1% and 10.1%); the five largest together contributed 39.1%.
- Seasonality includes lower Engineering and Life Sciences/IT activity as clients finalize first-quarter budgets and reduced Specialty Health Care activity during school summer recess. Management also notes labor-related health-care costs that it has not been able to pass through fully.
- The company accrued $2.9 million for asserted claims. A client dispute concerning an Industrial Processing project has a separate $0.5 million reserve; the company says potential damages may be contractually limited to $3.3 million and may be insured, but gives no assurance that those protections will apply.
- Material control weakness: Management and the auditor concluded internal control over financial reporting was ineffective, citing SAP/General Ledger segregation-of-duties and user-access-control deficiencies. The auditor issued an adverse opinion on internal controls, while issuing an unqualified opinion on the financial statements. Management said the weakness had not caused a financial-statement misstatement and identified remediation, including a planned SAP upgrade in 2024; timing of full remediation remains uncertain.
- The filing contains inconsistent deferred-revenue figures: the financial-statement note reports $1.9 million at year-end, while the MD&A describes a $0.3 million balance. Management also reports a $0.5–$1.0 million estimated cost for the financial-system upgrade. No dividends were declared in FY2022 or FY2023, and the credit agreement restricts dividends without lender consent.
Important facts for investors to verify
- Reconcile the deferred-revenue disclosure ($1.9 million in the note versus $0.3 million in MD&A) and confirm the correct year-end balance.
- Track remediation and independent testing of the material weakness, including completion of the SAP upgrade and user-access and segregation-of-duties controls.
- Assess whether operating cash flow recovers as receivables and EPC-related transit balances normalize; review customer payment and subcontractor obligations.
- Monitor borrowing levels, facility availability, interest expense and covenant headroom, especially given the variable-rate debt and repurchases.
- Evaluate customer concentration and the durability of Specialty Health Care demand after the decline in COVID-related activity; monitor segment utilization and margins.
- Follow developments in the Industrial Processing claim and other legal matters, including whether accrued reserves and insurance coverage prove adequate.